

STRATEGIC OPTIMIZATION OF RAPIDLY DISINTEGRATING TABLETS UTILIZING BOX-BEHNKEN EXPERIMENTAL DESIGN

Tushar Sonare, Aman Kumar, Kratika Khadsondni, Krutika Mandloi, Dr. Akash Yadav* and Dr. Dinesh Kumar Jain

IPS Academy College of Pharmacy, Knowledge Village, Rajendra Nagar, A.B. Road, Indore-452012, India.



***Corresponding Author: Dr. Akash Yadav**

IPS Academy College of Pharmacy, Knowledge Village, Rajendra Nagar, A.B. Road, Indore-452012, India.

Article Received on 06/02/2025

Article Revised on 26/02/2025

Article Accepted on 16/03/2025

ABSTRACT

This research thoroughly investigated the formulation of quickly disintegrating glipizide tablets, utilizing a Box–Behnken design in conjunction with the direct compression method. The study concentrated on using super-disintegrants such as cross-povidone and sodium starch glycolate, paired with the binder hydroxypropyl methylcellulose. Comprehensive pre-formulation tests were carried out to confirm the physicochemical compatibility of glipizide with the chosen excipients. The resulting fast-dissolving tablets underwent rigorous assessments, which included evaluating weight variation, mechanical strength, friability, disintegration time, in vitro drug release characteristics, and stability. By strategically applying the Box–Behnken design, the optimization of the synthetic super-disintegrants' ratios led to enhanced disintegration and an optimal release profile for the active pharmaceutical ingredient. This novel formulation of fast-dissolving glipizide tablets is anticipated to greatly enhance patient compliance, particularly for diabetic individuals who face challenges with swallowing, thereby potentially improving treatment effectiveness and overall disease management.

KEYWORDS: Glipizide, Box–Behnken design, rapidly disintegrating.

INTRODUCTION

Diabetes mellitus a chronic metabolic condition marked by elevated blood sugar levels, which can harm organs such as the liver, kidneys, eyes, and blood vessels over time. There are two primary forms: Type 1 and Type 2. Type 2 diabetes is the more prevalent type, mainly caused by insulin resistance or insufficient insulin production. It is being increasingly diagnosed among younger individuals due to rising rates of obesity, unhealthy diets, and a lack of physical exercise. In recent decades, the incidence of Type 2 diabetes has surged worldwide across all economic levels. Type 1 diabetes, an autoimmune disorder, generally arises during childhood or adolescence and leads to minimal or no insulin production. Managing both types of diabetes necessitate ongoing access to healthcare and insulin to prevent complications. With approximately 1.5 million fatalities each year, diabetes represents a major global health challenge. Addressing these epidemic calls for concerted global efforts to enhance healthcare, decrease obesity, and encourage healthier lifestyle choices by 2025.^[1-2]

Glipizide is a type of sulfonylurea that is utilized in the treatment of 2 diabetes mellitus by enhancing insulin production and increasing sensitivity to insulin. With a molecular weight of 445.536 g/mol, it reduces blood

glucose levels by prompting the pancreas to generate more insulin. Glipizide comes in various forms, including sustained-release tablets and oral solutions, and is included in important pharmacopoeias such as the Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), and United States Pharmacopoeia (USP). This medication is typically administered orally, and it has a biological half-life of 2 to 6 hours. Glipizide is mainly used for managing non-insulin-dependent diabetes (Type 2), providing a reliable way to control elevated blood sugar levels and enhancing the effectiveness of insulin, making it a crucial component in the management of Type 2 diabetes.^[3-4]




Fig. 1: Glipizide.

Fast Dissolving Tablets

Fast-dissolving tablets (FDTs) are innovative oral dosage forms designed to break down and release their active ingredients almost immediately when they come into contact with the oral mucosa, eliminating the need for water. These tablets are crafted to dissolve in just a few seconds to a minute, greatly enhancing patient compliance, especially for those with swallowing difficulties or dysphagia. FDTs often utilize superdisintegrants and are commonly used in situations that require a quick therapeutic effect, such as treating acute pain, nausea, or allergic reactions.

Ideal Characteristics of Fast dissolving tablets

- The tablet should break down quickly, within seconds to a minute, when placed in the mouth, without needing water for consumption.
- It is specifically designed for people with swallowing difficulties, promoting better adherence to therapy and allowing for easy administration.
- The formulation must allow for the rapid release of the active pharmaceutical ingredient (API), ensuring a fast onset of therapeutic action.
- The tablet should be appropriately sized for easy handling and swallowing, prioritizing convenience for users, especially those with special needs.
- The formulation needs to be carefully crafted to enhance the availability of the active ingredient, allowing for prompt therapeutic response.

ADVANTAGES

- Conventional dose forms require liquid for ingestion, whereas FDTs do not.
- This makes it easier for patients who travel or don't have water to comply.
- The bioavailability of insoluble medications is improved by rapid pill dissolving and disintegration.
- Conventional processing and packaging equipment allow the manufacturing of tablets at low cost.
- Tablets dissolve and absorb quickly in the mouth.^[5-6]



Fig. 2: Fast dissolving tablet.

Box-Behnken Experimental Design

Response Surface Methodology (RSM) is centered on examining the connection between control variables and response variables to enhance processes. An essential element of RSM is the careful design of experiments, which aids in reducing costs while considering factors like mixtures and levels. Several experimental designs, such as full factorial, Box-Behnken Design (BBD), and central composite designs, play a crucial role in optimization research. The Box-Behnken Design, frequently utilized in RSM and accessible through software like Design Expert (version 7.0, Stat-Ease Inc.), is particularly useful for investigating three-level experiments. It generally includes 15 experimental trials, alongside five repeated runs to guarantee trustworthy results and consistency. This design employs a second-order polynomial model to depict the relationships between input and output variables. By leveraging these experimental designs, researchers can expedite the optimization of processes in areas like pharmaceuticals. These designs enhance data collection and analysis, making the process more efficient and ultimately boosting research productivity. The Box-Behnken Design, in particular, is appreciated for its capacity to deliver dependable insights using fewer trials, thereby conserving resources while obtaining valuable information. In summary, utilizing RSM and effective experimental designs improves the speed and efficacy of research, aiding in the development of optimized processes and solutions.^[7-9]

Selected Independent variables and Dependent variables

The selected independent variables are displayed in Table 1.

Table 1: Independent variables with levels.

Factor	Name	Unit	Minimum	Maximum
A	Cross-Povidone	%	1	4
B	Sodium Starch Glycolate	%	2	10
C	Hydroxy propyl Methylcellulose	%	1	5

The selected Dependent variables are displayed in Table 2.

Table 2: Dependent variables.

Response	Variables	Unit
1.	Dissolution	(%)
2.	Disintegration time	Seconds
3.	Hardness	Kg/cm ²

Table 3: Formulation Runs as per Box-Behnken design.


Std	Runs	Independent Variables			Dependent Variables		
		Cross-povidone (mg)	Sodium Starch Glycolate (mg)	Hydroxy propyl Methylcellulose (mg)	Dissolution (%)	Disintegration (Second)	Hardness (Kg/cm ²)
13	1	2.5	6	3	93.81	19.43	2.6
12	2	2.5	2	3	94.82	21.86	2.9
5	3	4	6	1	90.17	16.78	2.1
2	4	2.5	2	5	96.34	22.03	2.4
4	5	4	10	3	98.43	14.23	2.3
6	6	2.5	2	1	95.17	21.29	2.1
10	7	1	6	1	95.43	22.65	2.2
1	8	1	10	3	91.39	18.31	2.4
15	9	2.5	10	5	94.82	16.27	2.3
14	10	1	6	5	93.12	21.89	2.6
8	11	1	2	3	97.47	22.23	2.8
3	12	4	6	5	95.17	16.42	2.4
7	13	2.5	6	3	93.27	19.12	2.8
11	14	2.5	10	1	91.65	16.10	2.9
9	15	2.5	6	3	92.87	19.82	2.3

MATERIALS AND METHODS

Glipizide was provided as a sample by USV Private Limited, located in the IInd Stage of Peenya Industrial Estate, Bangalore, Karnataka. Microcrystalline cellulose was sourced from Maple Biotech Pvt. Ltd., Pune, Maharashtra, while saccharin was obtained from Ranbaxy, New Delhi. Talc and magnesium stearate were supplied by S.D. Fine Chem Ltd., Mumbai, Maharashtra.

All other solvents and reagents for the formulation were procured from the market. These ingredients were carefully selected from reputable suppliers to ensure the final product's quality and effectiveness, maintaining high standards within the pharmaceutical industry. The attention to sourcing and quality control emphasizes the commitment to producing reliable and effective medications for end-users.

Table 4: Physical and chemical parameters of Glipizide.

S. No.	Parameter	Predicted value
1.	Molecular formula	C ₂₁ H ₂₇ N ₅ O ₄ S
2.	Molecular structure	
3.	IUPAC name	N-(4-[N-(cyclohexyl carbamoyl) sulfonyl] phenethyl)-5-methylpyrazine-2-carboxamide
4.	Molecular weight	445.536 g/mol
5.	BCS class	Class II
6.	pH and pKa	5.9 and 6.0
7.	Log P	1.91 or 1.83
8.	Crystallinity	Crystalline solid
9.	Melting point	208-209 °C (406 to 408 °F)
10.	Solubility	Soluble in organic solvents like methanol, acetone

Pre-Compression Parameters

Angle of repose: The maximum angle at which a build-up of loose powder remains stable without collapsing is known as the angle of repose. It acts as a gauge of the cohesiveness and flow properties of the powder. Better flow is indicated by lower angles, and worse flow is indicated by greater angles. A mound of powder is progressively built up on a level surface until it starts to slump in order to be measured.

$$\text{Angle of repose } (\tan\theta) = \frac{\text{Height of pile (h)}}{\text{Radius of the base pile (r)}}$$

Bulk Density: The mass of a powder divided by its whole volume, which includes the empty spaces between particles, is known as its bulk density. It is commonly given in quantities such as g/cm³ or kg/L and indicates how well the powder packs together. Using tools like a graduated cylinder, a known volume of the powder—including its vacant spaces—must be weighed in order to make a determination.

$$\text{Bulk density} = \frac{\text{Mass of bulk powder}}{\text{Volume of bulk powder}}$$

Tapped Density: The maximum bulk density attained when a powder is tapped or vibrated to remove interparticle gaps is known as "tapped density." The powder is tapped repeatedly in a container until no more volume loss takes place, indicating the powder's packing capabilities under compaction.

$$\text{Tapped density} = \frac{\text{Mass of bulk powder}}{\text{Final volume of tapped powder}}$$

Hausner's Ratio: Hausner's ratio is the ratio of tapped density to bulk density, calculated using the formula:

$$\text{Hausner's ratio} = \frac{\text{Tapped density}}{\text{Bulk density}}$$

It offers information about the packing efficiency and flow behavior of the powder. Good flowability is indicated by a ratio near 1, and poor flowability is indicated by values greater than 1.

Carr's Index: Carr's index, or compressibility index, quantifies the powder's compressibility and is calculated as follows:

$$\text{Carr's index} = \frac{\text{Tapped density} - \text{Bulk density}}{\text{Tapped density}} \times 100\%$$

It shows the extent of volume reduction brought about by compression or tapping. Superior flowability is indicated by lower Carr's index values, whereas reduced flow or enhanced cohesion are implied by higher values.

Partition Coefficient: Glipizide, a second-generation sulfonylurea utilized for the treatment of type 2 diabetes,

is a lipophilic substance with limited solubility in water. Its partition coefficient (Log P) is between 2.4 and 2.6, suggesting that it dissolves better in lipid environments compared to aqueous solutions. characteristic facilitates its passage through lipid membranes, enhancing oral absorption. However, an excessive degree of lipophilicity could impede its dissolution and bioavailability. In laboratory settings, the partition coefficient of Glipizide is measured by equilibrating it in n-Octanol and water, subsequently calculating the ratio of concentrations in both phases.

$$\text{Partition Coefficient}_{o/w} = \frac{\text{Concentration}_{oil}}{\text{Concentration}_{water}}$$

Glipizide identification studies: Glipizide 10mg was accurately weighed and dissolved in 10ml methanol and subsequent dilution was made to get required concentrations (1000µg/ml). The wave length of maximum absorbance (λ_{max}) of this clear solution was determined from 200-400nm methanol used as blank.

Preparation of stock solution: Glipizide 10 mg was dissolved in methanol 10 ml (1000 µg/ml) Stock solution I. From this solution diluted with methanol up to 100ml (100 µg/ml) Stock solution II was prepared.

Preparation of sample solution: Precise aliquots of 0.5, 1, 1.5, 2, and 2.5 ml were meticulously drawn from Stock Solution II and subsequently diluted to a final volume of 10 ml with a suitable solvent. This process yielded solutions with concentrations of 5, 10, 15, 20, and 25 µg/ml, respectively. The absorbance of each solution was measured at 268 nm using a UV-visible spectrophotometer (Model 1800), with each reading carefully compared against an appropriate blank to ensure accuracy and minimize deviations. The recorded absorbance values were systematically documented for further evaluation. A standard calibration curve was constructed by plotting the known concentrations on the X-axis against their corresponding absorbance values on the Y-axis. This graphical representation delineated a linear correlation between concentration and absorbance, conforming to Beer-Lambert's principle. The resulting equation of the calibration curve enabled the precise determination of unknown concentrations by interpolating their absorbance values within the established range. This analytical approach guarantees exceptional accuracy and reproducibility in quantitative assessments, making it highly applicable in pharmaceutical and scientific research. The developed calibration model serves as a fundamental reference for subsequent spectrophotometric analyses, thereby reinforcing the reliability and precision of experimental outcomes.

Melting point of Glipizide: The melting point of Glipizide was established using an electric melting point device. A capillary tube, sealed at one end, was filled with the drug sample and positioned in the appropriate

slot of the apparatus. The device was turned on, and the tube was monitored closely through the built-in magnifying glass for any indication of melting. The temperature at which the sample-initiated melting was carefully recorded from the thermometer. This initial temperature was noted as the melting point of the

sample. To guarantee accuracy and reliability, the procedure was repeated three times, and the average of the three measurements was taken as the definitive melting point value. This technique yielded dependable and precise results for characterizing Glipizide.^[10-14]

Table 5: Formulation of fast dissolving tablets.

Aspect	Fast dissolving tablets
Purpose	To provide rapid dissolution and absorption for fast onset of action.
Drug Release Mechanism	Drug dissolves quickly in the mouth or stomach.
Excipients	Super-disintegrants- Sodium starch glycolate, Cross-povidone Binders- Guar gum, PVPK-30 Lubricants- Magnesium stearate - Talc
Tablet size	Smaller and thinner due to rapid dissolution mechanism
Tablet Compression	needs to be compressed under low force to ensure quick dissolution.
Drug Release Profile	Rapid drug release within minutes, typically within 3-5 minutes of contact with water or saliva.
Preparation Methods	Direct compression or molding
Advantages	-Fast onset of action for immediate relief. - Convenient for patients with swallowing difficulties. - Enhanced patient compliance for medications that need to be taken urgently.

Table 6: Pharmacokinetic.

Pharmacokinetic Parameter	Fast Dissolving Tablets
Onset of Action	Faster onset due to rapid dissolution and absorption
Time to Peak Concentration (Tmax)	30-60 minutes (faster absorption)
Bioavailability	85-95% (similar to conventional tablets, but may have slight improvement in absorption due to faster dissolution)
Peak Plasma Concentration (Cmax)	Achieved faster
Volume of Distribution (Vd)	8-10 L/kg
Plasma Protein Binding	98-99%

Table 7: List of excipients used in formulations and their role.

Excipients	Role
Glipizide	Active Pharmaceutical ingredients
Cross-povidone	Super disintegrants
Sodium starch glycolate	Super disintegrants
Hydroxypropyl Methylcellulose	Binder
Talc	Glidant
Magnesium Stearate	Lubricant
Sodium saccharine	Sweetening agent
Microcrystalline cellulose	Filler

Post-compression Studies

➤ **Organoleptic characters:** Each batch of tablets is evaluated for sensory properties, including appearance, color, odor and shape, through direct observation and analysis.

➤ **Thickness and diameter:** Measure tablet thickness and diameter length using vernier caliper. Five tablets were selected from each batch and their measurements averaged to give a representative value expressed in millimeters.

➤ **Hardness:** Test the hardness of the tablets using the Monsanto hardness tester. Three pieces were selected from each map and the average hardness value was recorded. These values are expressed in kilograms per square centimeter (kg/cm^2).

➤ **Friability:** Friability of tablets was assessed using Roche friability tester as per the guidelines prescribed in Indian Pharmacopoeia (IP) standards. Initially, the weight of 20 pieces was recorded as the starting weight (W_i). Set the grinder to run at 25 revolutions per minute (rpm) for 4 minutes. Thereafter the tablets were reprocessed (W_f). Then, the friability percentage (%F) of

each batch of tablets was calculated using the given formula:

$$F = \frac{W_i - W_f}{W_i} \times 100$$

It is worth noting that friability should not exceed 1.0% as per the standards set by the United States Pharmacopoeia (USP), Indian Pharmacopoeia (IP) and British Pharmacopoeia (BP).

➤ **Weight variation:** Twenty tablets were selected from each batch before weighing, individual weight was measured and averaged. The weight was measured as per the specifications mentioned in the Indian Pharmacopoeia (I.P.). According to the I.P standard the average difference in weight should not exceed 5% and two tablets and no tablet should exceed two times the percentage.

$$\% \text{ Deviation} = \frac{\text{Wt. of each tablet} - \text{average Wt of tablet}}{\text{average Wt of tablet}} \times 100$$

➤ **In-vitro disintegration time:** Tablet disintegration time was evaluated using a USP disintegration tester in water maintained at $37 \pm 2^\circ\text{C}$. As standard partial disintegration, six tablets from each batch were placed in one liter of distilled water. The time required to complete disintegration of all six tablets was recorded. Ideally, the duration of all tablets should not exceed 3 minutes. If

Amount of drug release

$$= \frac{\text{Concentration} \times \text{dilution factor} \times \text{volume of dissolution medium}}{1000}$$

Stability Studies: In this study, all formulations were evaluated for one-month stability in accordance with the rapid study criteria established by the International Committee for Harmonization (ICH). The sample was carefully wrapped in aluminum foil and stored in airtight glass. The tablets were stored at three different temperatures. Over a period of 10, 20 and 30 days, the tablets are removed from storage and analyzed for physical properties, separation properties and drug content.^[15-21]

Formulation of Glipizide by using Direct Compression Method

Direct compression is a method used in tablet manufacturing where the ingredients of the formulation are combined, processed, and then pressed into tablets. This technique is particularly well-suited for tablets that include hygroscopic and thermolabile active pharmaceutical ingredients (APIs). It is preferred because of its straightforwardness and cost-efficiency when compared to other tablet compression methods. In

more than one tablet failed to meet this criterion, the study was repeated using 12 tablets. It is expected that no more than 2 out of 18 tablets will differ from the unseparated standards.

➤ **In-vitro dissolution studies:** The release rate of Glipizide tablets was evaluated using a USP Type II dissolution apparatus in paddle configuration. Place one tablet in 6 dissolution vials, each containing 900 ml of separation medium, pre-equilibrated at $37 \pm 0.5^\circ\text{C}$ and mixed at 50 rpm. At the appointed time, remove 2 ml aliquots of the dissolution medium and replace them with fresh dissolution medium. The sample was then filtered, diluted, and analyzed spectrophotometrically at 268 nm to determine the concentration of the drug relative to the corresponding concentration. This process is done on all batches. The average percentage of Glipizide released at different time points was determined from the sample image and plotted against time.

Calculation of % drug release involves the following steps

Determined concentration of drug released by using formula

$$Y = mx + c$$

Y is absorbance, m is slope, C is intercept, X is concentration ($\mu\text{g/ml}$)

direct compression, excipients and APIs are mixed into a powdered blend, with particle sizes regulated through the use of mills and sieves, and then they are compressed into tablets. This process demands minimal equipment and fewer steps, making it the most efficient and cost-effective approach for tablet production.

Ideal Characteristics of direct compression method

- Reduced processing steps lead to lower production expenses.
- When the formulation is appropriately designed, direct compression can yield tablets that have consistent weight, hardness, and dissolution characteristics.
- This approach needs fewer and simpler machines, making maintenance and operation easier.
- A decrease in handling steps and equipment diminishes the chances of contamination during production.
- Various excipients enable flexible formulations to meet diverse product requirements.^[22-23]




Fig. 3: Formulation of Fast Dissolving Tablets by using Direct Compression Method.

RESULT AND DISCUSSION

Organoleptic properties: Organoleptic properties of the drug sample were found to be as given in table below.

Table 8: Organoleptic properties of Glipizide.

S. No.	Organoleptic Characteristics	Result
1.	Color	White to off-white crystalline compound
2.	Nature	Crystalline powder
3.	Odour	Odorless
4.	Taste	Slightly bitter

Melting point of Glipizide: The final reading was obtained by averaging the results of three independent experiments, resulting in a temperature of 209°C.

Partition Coefficient: The partition coefficient of Glipizide is found to be 1.91.

pH determination of Glipizide: The pH range glipizide is adjusted to 6.8 to 7.0 during preparation to ensure that it is stable and effective in treating diabetes.

Solubility study of Glipizide: A solubility assessment was conducted to examine how Glipizide dissolves in methanol. During this experiment, different quantities of Glipizide were introduced into flasks that contained a consistent volume of methanol. The mixtures were

continuously stirred for 24 hours to guarantee that the drug fully dissolved. After the stirring process, the solutions were filtered to eliminate any undissolved Glipizide particles, resulting in a clear solution. The concentration of the dissolved Glipizide was determined using a UV-Vis spectrophotometer, comparing absorbance values with a calibration curve that correlated absorbance to known concentrations. By considering the amount of Glipizide added, the volume of methanol used, and the absorbance data, the solubility was calculated in milligrams per milliliter (mg/mL). This method could also be modified to investigate how temperature and various solvents impact Glipizide's solubility, offering useful insights for formulation development.

Table 9: Solubility of glipizide in solvents.

S. No.	Name of solvent	Solubility
1.	Methanol	Freely soluble
2.	Ethanol	Practically soluble
3.	Acetone	Slightly soluble
4.	Methylene chloride	Slightly soluble
5.	Water	Practically insoluble

Table 10: Flow properties of powder blend.

S. No	Angle of Repose (θ)	Bulk Density (g/cm^3)	Tapped Density (g/cm^3)	Hausner's Ratio	Carr's Ratio (%)
1.	33.26	0.52	0.64	1.23	18.40
2.	32.55	0.47	0.53	1.12	11.35
3.	31.74	0.52	0.60	1.15	13.38
4.	34.45	0.48	0.57	1.16	14.03
5.	33.23	0.55	0.64	1.12	10.93
6.	32.66	0.52	0.62	1.16	14.51
7.	30.36	0.48	0.55	1.14	12.77
8.	32.54	0.51	0.59	1.15	14.85
9.	33.18	0.49	0.62	1.15	16.92
10.	34.47	0.48	0.57	1.15	14.02
11.	33.23	0.53	0.65	1.23	18.40
12.	31.74	0.52	0.59	1.16	13.32
13.	33.22	0.56	0.64	1.11	10.92
14.	33.25	0.52	0.65	1.22	18.48
15.	32.52	0.51	0.58	1.19	14.84

Post-compression Studies

Organoleptic characters

Table 11: Organoleptic properties of Glipizide Tablets.

S. No.	Organoleptic Characteristics	Result
1.	Color	White to off-white
2.	Shape	Circular
3.	Odour	Odorless
4.	Taste	Palatably sweet

Identification of Glipizide by UV spectrophotometry

Derivation of drug spectrum: The methanol stock solution of Glipizide, with a concentration of $10\mu\text{g/ml}$, exhibited a peak absorption wavelength (λ_{max}) at 268 nm. The absorbance observed at this wavelength was measured to be 0.1404.

Preparation of calibration curve of Glipizide in water:

The calibration curve of glipizide dissolved in methanol was plotted using a UV spectrophotometer and measured at a wavelength of 268 nm. This curve was created from 5 dilutions of stock solution, each at $5\mu\text{g/ml}$. The resulting curve is shown in Table 13.

Table 12: Calibration curve data of Glipizide in methanol.

S. No.	Concentration ($\mu\text{g/ml}$)	Absorbance at 268
1	5	0.1404
2	10	0.2824
3	15	0.4513
4	20	0.5914
5	25	0.7170

Calibration curve of Glipizide
in Methanol at 268 nm




Fig. 4: Calibration curve of Glipizide.

Table 13: Post-compression parameters of tablets.

Formulation code	Thickness (mm)	Hardness (Kg/cm ²)	Friability (%)	Disintegration time (Sec)
FDT 1	1.96±0.2	1.9	0.40	20.16
FDT 2	2.02±0.2	1.8	0.42	21.48
FDT 3	1.99±0.2	2.1	0.48	19.46
FDT 4	2.01±0.2	1.9	0.43	20.12
FDT 5	2.0±0.2	2.3	0.44	22.12
FDT 6	1.98±0.2	1.8	0.47	20.12
FDT 7	1.99±0.2	1.9	0.56	19.48
FDT 8	2.02±0.2	2.0	0.58	20.12
FDT 9	1.98±0.2	1.9	0.44	20.11
FDT 10	1.99±0.2	1.8	0.43	18.42
FDT 11	2.01±0.2	1.9	0.47	19.49
FDT 12	2.00±0.2	2.1	0.45	19.40
FDT 13	1.97±0.2	2.0	0.49	20.13
FDT 14	1.99±0.2	1.8	0.48	22.16
FDT 15	2.01±0.2	1.9	0.49	24.11

In-vitro dissolution studies

Table 14: Cumulative drug release of Glipizide Tablets formulations (F1-F15).

Formulation code	Cumulative Drug Release (%)				
	Time (Minutes)				
	2.5	5	10	15	20
FDT 1	40.15	58.36	82.89	92.15	96.36
FDT 2	38.14	59.17	81.48	90.98	95.45
FDT 3	93.95	57.41	81.78	91.42	95.69
FDT 4	43.58	58.45	83.45	93.25	97.45
FDT 5	41.26	57.41	81.45	90.87	94.45
FDT 6	42.45	58.45	83.45	93.45	94.24
FDT 7	46.15	60.32	88.18	98.14	99.13
FDT 8	51.35	62.45	89.45	99.48	99.71
FDT 9	49.65	59.65	85.48	95.89	98.45
FDT 10	50.45	58.45	84.65	97.89	98.45
FDT 11	40.96	57.24	81.57	92.75	96.78
FDT 12	42.98	58.45	83.48	93.25	94.48
FDT 13	42.48	58.48	84.16	93.24	94.89
FDT 14	46.48	59.14	88.14	98.89	98.59
FDT 15	51.48	62.56	89.58	99.58	99.58




Fig. 5: Cumulative drug release of Glipizide Tablets (F1-F15).

- ❖ Response data for all 15 batches by using Box-Behnken Experimental Design (FI-F15).

Response 1: Dissolution (%)




Fig. 6: The 2D contour plot and the three-dimensional 3D map shows how the total amounts of super disintegrates (X1) and (X2) affect the dissolution.

ANOVA for Linear model

Response 1: Dissolution.

Source	Sum of Squares	df	Mean Square	F-value	p-value	
Model	59.35	6	9.89	6.32	0.0102	significant
A-Cross Povidone	0.9059	1	0.9059	0.5792	0.4684	
B-Sodium Starch Glycolate	1.54	1	1.54	0.9844	0.3502	
C-Hydroxy propyl Methylcellulose	6.18	1	6.18	3.95	0.0821	
AB	31.41	1	31.41	20.08	0.0021	
AC	13.36	1	13.36	8.54	0.0192	
BC	1.00	1	1.00	0.6394	0.4470	
Residual	12.51	8	1.56			
Lack of fit	12.07	6	2.01	9.04	0.1030	Not significant
Pure Error	0.4451	2	0.2225			
Cor Total	71.86	14				

Response 2: Disintegrating time (Second).




Fig. 7: The 2D contour plot and the three-dimensional 3D map shows how the total amounts of super disintegrates (X1) and (X2) affect the disintegration time.

ANOVA for Linear model

Response 2: Disintegration Time.

Source	Sum of Squares	df	Mean Square	F-value	p-value	
Model	99.07	3	33.02	56.72	<0.0001	significant
A-Cross Povidone	35.78	1	35.78	61.46	<0.0001	
B-Sodium Starch Glycolate	50.12	1	50.12	86.09	<0.0001	
C-Hydroxy propyl Methylcellulose	0.0055	1	0.0055	0.0095	0.9242	
Residual	6.40	11	0.5822			
Lack of fit	6.16	9	0.6843	5.56	0.1616	Not significant
Pure Error	0.2461	2	0.1230			
Cure Total	105.48	14				


Response 3: Hardness (Kg/cm^2).

Fig. 8: The 2D contour plot and the three-dimensional 3D map shows how the total amounts of super disintegrates (X1) and (X2) affect the Hardness.

ANOVA for Linear model

Response 3: Hardness.

Source	Sum of Squares	df	Mean Square	F-value	p-value	
Model	0.0000	0				
Residual	1.07	14	0.0764			
Lack of fit	0.9427	12	0.0786	1.24	0.5307	Not Significant
Pure Error	0.1267	2	0.0633			
Core Total	1.07	14				

Table 15: pre compressional data of optimized batch (FDT 16).

S. No.	Pre-compressional evaluation parameter	Results
1.	Bulk density	0.48 g/cm^2
2.	Tapped density	0.62 g/cm^2
3.	Hausner's ratio	1.29
4.	Carss index	22.58%
5.	Angle of repose	$\sim 30^\circ$ to 35°

Table 16: post compressional data of optimized batch (FDT 16).

S. No.	Post-compression evaluation parameter	Results
1.	Thickness	2.98±0.2mm
2.	Hardness	2.357 kg/cm ²
3.	Disintegration time	13.8 seconds
4.	Friability	0.49 %
5.	% Drug release	97.981 %

Table 17: In vitro drug release for optimized batch (FDT 1)

Formulation batch	2.5 min	5 min	10 min	15 min	20 min
FDT 1	42.17	59.89	77.89	89.69	98.56




Fig. 9: Percent drug release of batch FDT 1 (optimised batch).

The obtained Percent drug release of batch ODT 16 (optimised batch) has 97.21% of drug release in 20 minutes, and the optimized batch was evaluated for all the pre and post compressional parameters required for quality control of dosage form and the obtained results was found between satisfied range.

Stability Studies

The stability studies of fast-dissolving tablets of Glipizide at a 100 mg dose indicated that the best formulation remained stable even after storing at 40±20°C / 75±5% RH for 3 months. The tablets were visually examined for any physical changes, evaluated for drug content, and in vitro drug release at monthly intervals. The results showed that the formulation maintained its drug release profile within the specified limits, demonstrating stability over the study period.

CONCLUSION

This study has convincingly shown the effectiveness of using a Box–Behnken design to improve the of fast-dissolving glipizide tablets through direct compression. A thorough investigation into the combined effects of super-disintegrants specifically cross-povidone and sodium starch glycolate alongside hydroxypropyl methylcellulose as the binder, resulted in a formulation that features significantly quick disintegration and an enhanced drug release profile. This innovative dosage form effectively addresses important issues in managing Type 2 diabetes, specifically helping patients with dysphagia who require a treatment that is easy to take.

The rapid dissolution of the tablets, which eliminates the need for water, greatly enhances patient adherence and treatment effectiveness. Given the ongoing global health challenges posed by diabetes, these results represent a significant step forward in patient-focused drug delivery systems, highlighting the value of the Box–Behnken design in pharmaceutical development and paving the way for future advancements in the treatment of chronic metabolic conditions.

ACKNOWLEDGEMENT: I want to express my sincere thanks to IPS Academy College of Pharmacy for providing the vital resources and facilities that significantly aided my academic path. I also truly appreciate the invaluable support and engaging conversations I had with my colleagues and peers. Their encouragement, helpful feedback, and emotional support were crucial to achieving success in this project. I am genuinely grateful for their contributions, which have been essential to completing this work.

CONFLICT OF INTEREST: The authors declare no conflict of interest.

REFERENCES

1. Parasuraman S, Thinakaran JN. Evaluation of the antidiabetic activity of hesperidin on streptozotocin-induced diabetes mellitus in Swiss albino mice. *Free Radicals and Antioxidants*, 2023; 13(1): 46-49.
2. Tiwary N, Sharma N, Singh S, Behl T, Zahoor I. Understanding the Pharmacological and

- Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics. *BioNanoScience.*, 2024 Mar; 14(1): 211-29.
3. Li Z, Mei S, Dong Y, She F, Li Y, Li P, Kong L. Functional nanofibrous biomaterials of tailored structures for drug delivery a critical review. *Pharmaceutics*, 2020; 12(6): 522.
 4. El-Dakrouy WA, Zewail MB, Amin MM. Design, optimization, and in-vivo performance of glipizide-loaded O-carboxymethyl chitosan nanoparticles in insulin resistant/type 2 diabetic rat model. *Journal of Drug Delivery Science and Technology*, 2023; 79: 104040.
 5. Omar SM, AbdAlla FI, Abdelgawad NM. Preparation and optimization of fast-disintegrating tablet containing naratriptan hydrochloride using D-optimal mixture design. *AAPS PharmSciTech*, 2018 Aug; 19: 2472-87.
 6. Alburyhi MM, Saif AA, Noman MA, Yahya TA, Al-Ghorafi MA. Formulation and Evaluation of Drotaverine Orally Disintegrating Tablets. *World Journal of Pharmaceutical Research*, 2023 Sep 5; 12(18): 66-79.
 7. Singh A, Chauhan CS. Formulation and optimization of valganciclovir-loaded nano sponges. *International Journal of Drug Delivery Technology*, 2024; 14(1): 1-8. 15. Sharma S, Chauhan S. A review: An overview of Natural super disintegrants. *Research Journal of Topical and Cosmetic Sciences*, 2021; 12(1): 13-24.
 8. Roy H, Nandi S, Pavani U, Lakshmi U, Reddy TS, Gayatri DV. Optimization and quality by design approach for iroxicam fast dissolving tablet formulations using Box-Behnken design. *Current Drug Therapy*, 2020; 15(2): 152-65.
 9. Sharma S, Chauhan S. A review: An overview of Natural super disintegrants. *Research Journal of Topical and Cosmetic Sciences*, 2021; 12(1): 13-24.
 10. Butola M, Bhatt V, Nainwal N, Jakhmola V, Dobhal K, Ale Y. Preparation and evaluation of polymer fused metformin hydrochloride sustained release tablet. *Indian Journal of Pharmaceutical Education and Research*, 2023; 57(3): 711-7.
 11. Kakad SB, Rachh PR. Effect of hydrophilic polymer and binder on drug release of metformin HCl sustained release tablet. *International Journal of Health Sciences*, 2022; 3343-6635. 4.
 12. Tomar A, Wadhwani S, Bhadauria RS. A preformulation study of pure Metformin HCl. *International Journal of Pharmaceutical Erudition*, 2019; 8(4): 1-9.
 13. Tyagia L. A comprehensive review on superdisintegrants: accelerating dissolution for enhanced drug performance: *International Journal of Medical Science*, 2024 Jun; 20: 34-49.
 14. Othman AM, Alburyhi MM, Al-Hadad GH. Formulation and Evaluation of Captopril Mouth Dissolving Tablets. *European Journal of Pharmaceutical and Medical Research*, 2024; 11(1): 18-28.
 15. Kusuma AN, Kumar RS. Optimization of fast-dissolving tablets of carvedilol using 23 factorial designs. *International Journal of Applied Pharmaceutics*, 2024; (1): 98-107.
 16. Gupta A, Yadav A, Jain DK. Fast dissolving tablets for the treatment of acute and chronic diseases. *International Journal of Pharmaceutical Drug Design*, 2024; 1(2): 1-8.
 17. Turanli Y, Birer M, Birer YT, Uyar R, Dikmen BY, Acartürk F. Oral fast-dissolving risperidone loaded electrospun nanofiber drug delivery systems for antipsychotic therapy. *Journal of Drug Delivery Science and Technology*, 2024; 92: 1-9.
 18. Alburyhi MM, Noman MA, Saif AA, Salim YA, Abdullah JH. Formulation and evaluation of domperidone orodispersible tablets. *World Journal of Pharmacy and Pharmaceutical Sciences*. 2024; 13(3): 49-68.
 19. Chatterjee A, Gupta R. Formulation and evaluation of fast dissolving tablets of piroxicam using various concentration of different super disintegrating agents. *International Journal of Health Advancement and Clinical Research*, 2023; 1(4): 90-7.
 20. Akdag Y, Gulsun T, Izat N, Cetin M, Oner L, Sahin S. Evaluation of preparation methods for orally disintegrating tablets. *Medicine*, 2020; 9(1): 265-9.
 21. Akdag Y, Gulsun T, Izat N, Cetin M, Oner L, Sahin S. Characterization and comparison of deferasirox fast disintegrating tablets prepared by direct compression and lyophilization methods. *Journal of Drug Delivery Science and Technology*, 2020; 57: 101760-72.
 22. Kumar N, Pahuja S. Dispersible Tablets: An Overview. *Journal of Medical Pharmaceutical and Allied Sciences*, 2019 June 19; 8: 2183-99.
 23. Gandhi L, Akhtar S. Comparative study on effect of natural and synthetic superdisintegrants in the formulation of orodispersible tablets. *Journal of Drug Delivery and Therapeutics*, 2019 Mar 15; 9(2): 507-13.